Cardinal Health Inc
CAH: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$823.00 | Ggbnjt | Pcmpyrxgb |
Nonrenewal of OptumRx Contracts Throws a Wrench in Cardinal's Near-Term Dynamics
Business Strategy and Outlook
Cardinal Health is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With roughly $190 billion in annual US drug distribution sales in fiscal 2023, the company supplies roughly one fourth of the overall market. Its two close competitors are Cencora and McKesson. Together, the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.